How to Read a Drug-level Chart: Peaks, Dips and Buildup

A drug-level chart helps you see when doses overlap, where levels peak and how they fall between doses. Start with the axis label: concentration, relative units and percent of a curve’s own peak mean different things. None is a direct measure of benefit.

Read one curve from left to right

Peaks, troughs and buildup

Modeled timing, not a blood test

All six doses together First dose only

1 Peak

The high point after a dose. Absorption takes time, so it occurs after the input.

2 Trough

The low point between doses. Earlier drug can still be present.

3 Buildup

The solid line rises above the first-dose tail as earlier and newer doses overlap.

Study scope and example assumptions

Calculated from the site's existing Petri 2018 reference: an 85 kg woman under 65 with type 2 diabetes and normal renal function, using subcutaneous semaglutide. The published reference also fixes race/ethnicity as white and non-Hispanic and administration in the abdomen.

First-order absorption and elimination are held fixed. The source used ongoing-treatment data with a fixed absorption rate; this zero-history illustration extrapolates early-dose timing and omits clinical initiation and dose escalation. It predicts neither individual blood levels nor appetite, weight loss or potency. Original population-model study

The solid line combines all six inputs. The dashed line follows only the first: it keeps fading while newer doses add to the total. Later hills become more similar as the unchanged schedule approaches a repeating pattern.

Open the plotter alongside this guide to inspect a curve, or read the semaglutide model notes for the example above.

Read any plot in this order

1. 1

   Read both axes

   Check the time scale, concentration unit and which substance is being modeled.

2. 2

   Identify the model

   Check the source and whether the line is a reference calculation, a reconstructed estimate or a relative timing curve.

3. 3

   Inspect dose events

   Find the actual amounts and times. Peaks can occur later because absorption takes time.

4. 4

   Compare one change

   Keep the amount basis and units consistent when comparing schedules. A smoother line is a mathematical result, not proof of better health.

One dose: the rise, peak and fall

After a subcutaneous dose, drug enters the circulation while distribution and elimination are already occurring. The resulting peak is Cmax; its timing is Tmax. A peak is not necessarily the time of greatest benefit or side effects, because the body’s response can lag behind concentration.

Half-life describes a halving over a specified phase. In a simple first-order elimination example with no further input:

These are calculated values, 100 × 2 to the power of −n, not measured blood samples. Absorption, distribution and repeated input can make a real concentration curve more complex. Five half-lives is not “zero drug.”

Why a new dose starts before the old one is gone

Each new dose can overlap with earlier ones. Peaks rise after absorption; a trough is the low point within a dosing interval, commonly just before the next dose. A subcutaneous peak is not an instantaneous jump at injection.

Why the line eventually settles into a pattern

With an unchanged repeating schedule and linear kinetics, the pattern eventually repeats: average input and elimination balance. Peaks and troughs still occur. The familiar four-to-five-half-life rule means close to the repeating pattern, not an exact finish line or proof of full clinical effect.

A dose change starts a transition from the exposure already present. It does not reset the body to an empty starting point.

How much does the line swing?

This divides the interval’s highest concentration by its lowest. It describes fluctuation. Under many linear models, dividing the same total amount into more frequent inputs lowers peaks and raises troughs, but the size of that change depends on absorption and elimination. It is not universally “halved,” and does not prove fewer side effects.

Why levels build up over the first weeks

Accumulation is buildup from residual earlier doses. For a simple instantaneous-input model dosed once per half-life, the dose-normalized peak approaches twice the first peak. That textbook example does not mean every subcutaneous medicine’s measured peak or trough doubles. Its absorption profile matters.

Does a shorter half-life mean more doses?

Half-life helps explain an established regimen. It does not select one by itself: formulation, therapeutic targets, tolerability and clinical evidence also matter. A weekly medicine can have a shorter-than-seven-day half-life because useful exposure remains between doses.

Use the plotter to understand a prescribed or hypothetical schedule, and the GLP-1 explainer for a worked weekly example.

What the curve can’t tell you

The site’s available curves have three different kinds of support. Read the label beside the result:

Percent of own peak is a separate display option: each curve’s highest point is set to 100%. It helps compare shapes, including different substances. It is not the percent of a dose remaining or a strength comparison.

Even an absolute concentration model may represent only the administered drug’s contribution, rather than a hormone’s total blood level. Read the methodology and compound notes before comparing it with a laboratory reference range.

Frequently asked questions

Why does my curve show levels still climbing after several weeks?

Earlier doses are still contributing, or the schedule is still changing. Check the half-life, modeled absorption and dose history.

Should a blood test be taken at trough?

Follow the clinician’s timing instructions for the particular treatment and test. Trough sampling is not universal, and routine GLP-1 drug-concentration testing is not established by this plot.

How accurate are the concentration numbers?

Accuracy depends on the model’s evidence, inputs and how closely its population and formulation match. A plausible curve shape alone cannot validate its absolute values or exact timing.

What’s the difference between the curve and a real blood test?

The curve calculates a value from assumptions; a test measures a particular analyte at a particular time. They only become comparable when analyte, units and clinical context match.

Sources

Model sources and calculation notes

Checked October 11, 2026.

• The methodology explains reference, estimated and relative models, units and normalization.
• Petri et al., semaglutide population PK supplies the example’s existing reference model. The figure uses six equal weekly 1 mg inputs and zero prior exposure. Full context and first-dose extrapolation are in its disclosure; the studied treatment-starting schedule was different.
• Ozempic prescribing information, section 12.3 describes gradual absorption, an approximately one-week half-life and steady-state exposure after four to five weeks of weekly dosing. Those label summaries are not exact first-dose predictions for the fixed reference shown here.
• The half-life table is calculated as 100 × 2⁻ⁿ. It describes a single first-order decay without continuing input, not the absorption curve above or measured blood samples.